This article is more than 5 years old. Information may no longer be current.

VIDEO: Ibalizumab continues to suppress MDR HIV after 48 weeks

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — In this video, Brinda Emu, MD, assistant professor of medicine at Yale University, reviews 48-week data of a phase 3 trial evaluating the safety and efficacy of ibalizumab in patients with multidrug-resistant HIV.

Ibalizumab is a long-acting humanized monoclonal antibody administered intravenously every 2 weeks to patients on a failing HIV drug regimen. It is currently undergoing regulatory review in the United States and represents the first new class of antiretrovirals to be submitted for approval in the past 10 years, according to Emu.

Data presented at IDWeek showed that 59% patients with multidrug-resistant HIV receiving ibalizumab in combination with an optimized background regimen were virally suppressed after 48 weeks of treatment.

“Ibalizumab, with an optimized background regimen, has durable viral suppression for these very difficult-to-treat patients,” Emu says.

Reference:

Emu B, et al. Abstract 1686. Presented at: IDWeek; Oct. 4-8, 2017; San Diego.

Disclosure: Emu reports being a consultant for and shareholder of 3VBioscences, Achaogen, Genentech, MedImmune and Theratechnologies.